Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, October 8, 2026 – Life Biosciences (“Life Bio”), ...
BOSTON, October 1, 2026 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the company will present ...
Lead epigenetic restoration therapy enters the clinic for glaucoma and NAION, targeting a root cause of age-related vision loss BOSTON, June 9, 2026 — Life Biosciences, Inc. (“Life Bio”), a ...
Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates from the company’s Partial Epigenetic Reprogramming platform BOSTON, April 8, ...
BOSTON, January 28, 2026 – Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced ...
BOSTON, January 27, 2025 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the ...
Forge to provide cGMP manufacturing and development services for Life Biosciences’ novel adeno-associated virus (AAV) gene therapy platform for aging-related diseases, including in ophthalmic ...
As we age, our DNA sequence (genetic code) stays mostly the same throughout life. But the epigenetic code (which controls which genes are turned on or off) changes over time, contributing to gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results